Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Who We Serve
Individual Investors
Institutional Investors
What We Do
Trading
Individual Investing
Institutional Trading
Data
Liquidity Programs
Retirement
Self-Directed IRA
Insights
Reports and highlights
News and trends
Private market education
Tips and tutorials
About
Log In
Sign Up
Secondary marketplace / Explore private companies / BioAge IPO
BioAge

BioAge IPO

$440.23MM
Series D Valuation, Feb 2024
Completed IPO
Learn More About BioAge Stock
Register for details
For more details on financing and valuation of private companies similar to BioAge before its IPO, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

BioAge IPO date and status

2015
Founded
Aug 2024
S-1 Filed
www.sec.gov
Sep 2024
IPO Completed
www.globenewswire.com

Company details

BioAge develops a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging by using its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging.
bioagelabs.com
Sector
Healthcare
Subsector
Biotech & Pharma
Founded
2015
Headquarters
Richmond, CA, United States
Founders
Eric Morgen, M.D., Kristen Fortney, Ph.D.
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Get Full Access
Post-Money Valuation 3
$440.23MM
Total Funding
$1.42B
Last Funding Round
Series D

Learn more about BioAge

To invest in BioAge pre-IPO

Can you invest in BioAge pre-IPO?

You may invest in BioAge as it is a public company listed on the NASDAQ with ticker BIOA. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of BioAge before it goes public?

You can no longer sell shares of BioAge on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my BioAge shares?

Forge can no longer determine the value of BioAge shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is BioAge a publicly traded company?

BioAge became a public company following its IPO on 09/26/2024 and is now traded on the NASDAQ under the ticker BIOA.

To learn more about BioAge potential IPO

Will BioAge go IPO?

BioAge became a public company following its IPO on 09/26/2024 and is now traded on the NASDAQ under the ticker BIOA.

What is BioAge’s IPO price?

The IPO price of BioAge is not currently available.

When was BioAge founded?

BioAge was founded in 2015.

What is BioAge funding to date?

BioAge has raised $1.42B to date.

BioAge major investors

Aarp Foundation
Ame Cloud Ventures
Amgen
Andreessen Horowitz
Bossanova Investimentos
Caffeinated Capital
Cormorant Asset Management
Csc Upshot Ventures
Felicis
Green Sands Equity
Khosla Ventures
Longitude Capital
Orbimed
Osage University Partners
Pear Vc
Pivotal Bioventure Partners
Ra Capital Management
Redpoint Ventures
Rtw Investments
Sands Capital
Sofinnova Investments
Springboard Enterprises
Summer Vc
Summit Peak Investments
Show All InvestorsShow Fewer Investors

BioAge pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
02/13/2024 Series D $170MM $3.42 $440.23MM Amgen Ventures, Andreessen Horowitz, Cormorant Asset Management, Lilly Ventures, Longitude Capital, Orbimed Advisors, Osage University Partners, Pivotal Bioventure Partners, Ra Capital, Rtw Investments, Sands Capital, Sofinnova Investments, Sv Health Investors
Price per Share
$ xx.xx
Shares Outstanding
49,713,403
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, Andreessen Horowitz, Cormorant Asset Management, Lilly Ventures, Longitude Capital, Orbimed Advisors, Osage University Partners, Pivotal Bioventure Partners, Ra Capital, Rtw Investments, Sands Capital, Sofinnova Investments, Sv Health Investors
02/13/2024 Series D-1 $24.39MM $2.05 $440.23MM Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
11,887,535
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
12/03/2020 Series C $95MM $5.91 $270.18MM Aarp Foundation, Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Kaiser Foundation Hospitals, Pear Ventures, Phi-X Capital, Redpoint Ventures
Price per Share
$ xx.xx
Shares Outstanding
16,076,886
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Aarp Foundation, Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Kaiser Foundation Hospitals, Pear Ventures, Phi-X Capital, Redpoint Ventures
01/24/2019 Series B $22.93MM $3.08 $86.05MM Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Felicis Ventures, Khosla Ventures, Pear Ventures, Redpoint Ventures
Price per Share
$ xx.xx
Shares Outstanding
7,455,241
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Felicis Ventures, Khosla Ventures, Pear Ventures, Redpoint Ventures
07/28/2017 Series A-1 $11.82MM $2.49 $43.84MM Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
Price per Share
$ xx.xx
Shares Outstanding
4,753,466
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
07/28/2017 Series A-4 $54,998.51 $1.99 $43.84MM Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
Price per Share
$ xx.xx
Shares Outstanding
27,643
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
07/28/2017 Series A-3 $250,006.84 $1.23 $43.84MM Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
Price per Share
$ xx.xx
Shares Outstanding
203,821
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
07/28/2017 Series A-2 $1.81MM $0.61 $43.84MM Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
Price per Share
$ xx.xx
Shares Outstanding
2,948,071
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures

BioAge IPO news and media highlights

Yahoo Finance 10/07/2024

RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc

On September 27, 2024, RA Capital Management, L.P., a prominent investment firm, made a significant move in the biopharmaceutical sector by acquiring 2,210,589 shares of Bioage Labs Inc (NASDAQ:BIOA). This transaction, valued at $21 per share, marks a new holding for the firm, reflecting a strategic investment in the healthcare industry. The acquisition not only diversifies RA Capital's portfolio but also underscores its commitment to investing in innovative companies tackling major healthcare challenges.
Seeking Alpha 09/23/2024

BioAge Labs Readies $135 Million U.S. IPO To Advance Obesity Treatments

BioAge Labs (BIOA) has filed proposed terms to raise $135 million from the sale of its common stock in an IPO, according to an amended SEC registration statement. The company is a clinical-stage biopharma developing treatments for various metabolic diseases. Early trial results in combination with existing approved drugs have been encouraging and the company is well-capitalized and backed by a large syndicate of well-known venture capital, private equity and strategic investors.
FierceBiotech 02/13/2024

GLP-1 enthusiasm pushes BioAge Labs into new age with $170M series D

Until last year, BioAge Labs' progress could be best described as a slow burn, with a pipeline of longevity-focused medicines taking shape incrementally but consistently. The frenzy around GLP-1s changed all of that, with BioAge’s profile ascending dramatically thanks to being one of a select few biotechs with a combo candidate that might enhance weight loss without muscle loss. Equipped with that potential, and a partnership with Eli Lilly to test the hypothesis, BioAge has closed a $170 million series D led by Sofinnova with contributions from major institutional biotech investors and the venture arms of both the Indianapolis pharma and Amgen.
Reuters 02/13/2024

Eli Lilly partner BioAge raises $170 mln for obesity treatment

BioAge Labs, a biotech startup collaborating with Eli Lilly (LLY.N), opens new tab for trialing its obesity therapy, said on Tuesday it had raised $170 million in its latest funding round.
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
Generate BiomedicinesGenerate BiomedicinesNot available$ xx.xxSeries C$2.22B$11.85$399.4MM
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM
OriginOriginNot available$ xx.xxNot available------
See Tech IPO Calendar

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Actively traded

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
SpaceX SpaceX $601.27 +$4.10 (0.69%)High $xxx.xx
Anduril Anduril $110.97 +$4.00 (3.74%)High $xxx.xx
Databricks Databricks $197.65 -$0.01 (0.01%)High $xxx.xx
See All Actively Traded Companies

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
Anduril Anduril $110.97 +$4.00 (3.74%)High $xxx.xx
Databricks Databricks $197.65 -$0.01 (0.01%)High $xxx.xx
Perplexity Perplexity $69.54 +$6.59 (10.47%)High $xxx.xx
See All AI Companies

Forge, your trusted partner for pre-IPO insights and BioAge data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Register

Updated on: Jul 16, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.